HomeEXECUTIVESOxular Announces the Appointment of Dr. Friedrich Asmus as Chief Medical Officer

Oxular Announces the Appointment of Dr. Friedrich Asmus as Chief Medical Officer

Oxular Limited, a leading retinal therapeutics development company, today announces it has appointed Dr. Friedrich (Fritz) Asmus as Chief Medical Officer. Dr. Asmus will lead all medical, clinical, and regulatory functions to further the Company’s lead asset, OXU–001, for the treatment of diabetic macular edema (DME), and to accelerate the development of its early-product pipeline.

Dr. Asmus is a board-certified neurologist and pharmacist and, for more than 10 years, has successfully headed clinical development programs in the US, Europe, and Asia. Fritz was a key strategic leader in the successful development of alfibercept and other ophthalmic therapies at Bayer Pharma, including indications for DME, diabetic retinopathy, and retinal vein occlusions. Fritz also led development activities for rare ophthalmic diseases at ProQR Therapeutics and jCyte, where he headed the intravitreal oligonucleotide program for genetic forms of Retinitis pigmentosa (RP) and clinical development for an intravitreal cell therapy program for RP, respectively. Fritz holds a private lectureship for Neurology at the University Hospital of Tuebingen, Germany, where he was also Deputy Chair of the Department of General Neurology. He has published over 50 peer-reviewed articles in ophthalmology and neurology.

Prof. Marc D. de Smet, who has served as Oxular’s Chief Medical Officer in a part time capacity alongside his private clinical practice, will continue working with the Company as Senior Medical Advisor, bringing his world-leading retinal expertise to the ongoing development of the Company’s programs and technology.

Fritz’s appointment follows Oxular’s successful completion of a $37m financing in March 2021 and is a significant milestone in building the Oxular team to support future clinical trials and expanded R&D activities. Fritz joins as Oxular prepares to initiate human clinical trials for its lead asset, OXU-001, an extended-duration treatment for DME.

Thomas Cavanagh, Chief Executive Officer of Oxular, commented: “We are pleased to have Fritz join our leadership team, especially at this critical time when we are readying OXU–001 to begin human clinical studies and accelerating further the development of our highly differentiated product pipeline. Fritz’s depth of knowledge and experience in back-of-eye therapies will be highly advantageous in delivering on our pipeline’s promise of effective and longer-lasting treatments that offer patients truly life-changing solutions to their unmet needs.

“I’d like to acknowledge and thank Prof. de Smet for his incredible work over the last three years. The Company would not have advanced this far without his advice and expertise, and I look forward to continuing to work with Marc as the Company’s programs begin human clinical trials and as we expand use of Oxulumis™ (suprachoroidal space, illuminated microcatheter) to deliver important treatments for sight threatening diseases.”

Dr. Friedrich Asmus, Chief Medical Officer of Oxular, commented: “I have been really impressed with the work scientists at Oxular have delivered in supporting an expanded role of drug delivery to the suprachoroidal space. It is a great privilege to be part of Oxular’s team, driving outstanding innovation to establish an entire product platform of suprachoroidal therapies for areas of high unmet patient need in common and ultra-rare ophthalmic indications.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

Skyhawk Therapeutics Completes New Investment Round

A $133 million round of investment will allow Skyhawk to accelerate development of its novel small molecule RNA-modifying drug candidates into the clinic.

By using this website you agree to accept Medical Device News Magazine Privacy Policy